{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27
  ],
  "modelUsed": "gemini-2.5-pro",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ALXN1840 Treatment",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "All participants receive ALXN1840 at an initial dose of 15 mg/day for approximately 28 days, followed by titration up to 30 mg/day starting on Day 29.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '15 mg/day', 'startDay': 1, 'endDay': 28, 'description': 'Initial dose period'}, {'dose': '30 mg/day', 'startDay': 29, 'description': 'Titrated dose period'}]"
          }
        ]
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Cohort 1 (treatment experienced)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received WD therapy for > 28 days"
      },
      {
        "id": "cohort_2",
        "name": "Cohort 2 (treatment naïve)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received WD therapy for ≤ 28 days"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 4,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Wilson Disease"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": null,
      "therapeuticAreas": [
        "Wilson Disease"
      ]
    },
    "arms": [
      {
        "name": "ALXN1840 Treatment",
        "type": "Experimental",
        "description": "All participants receive ALXN1840 at an initial dose of 15 mg/day for approximately 28 days, followed by titration up to 30 mg/day starting on Day 29.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "15 mg/day",
            "startDay": 1,
            "endDay": 28,
            "description": "Initial dose period"
          },
          {
            "dose": "30 mg/day",
            "startDay": 29,
            "endDay": null,
            "description": "Titrated dose period"
          }
        ]
      }
    ],
    "cohorts": [
      {
        "name": "Cohort 1 (treatment experienced)",
        "characteristic": "Patients who have received WD therapy for > 28 days"
      },
      {
        "name": "Cohort 2 (treatment naïve)",
        "characteristic": "Patients who have received WD therapy for ≤ 28 days"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Period to determine participant eligibility."
      },
      {
        "name": "Run-in Period",
        "description": "Day -8 to Day -1. Includes diet equilibration and measurement of pretreatment copper and molybdenum balance."
      },
      {
        "name": "Treatment Period 1 (15mg)",
        "description": "Day 1 to Day 28. Participants receive ALXN1840 15 mg/day."
      },
      {
        "name": "Treatment Period 2 (30mg)",
        "description": "Day 29 onwards. Participants receive ALXN1840 30 mg/day after titration."
      }
    ]
  }
}